- RG7128 - is being developed by Pharmasset and Roche www.pharmasset.com/pipeline/rg7128.aspx which is a complete underhanded tactic by Roche to squeeze Pharmasset out of the game because their recent purchase of Anadys Pharmaceuticals seekingalpha.com/news-article/2026824-sector-snap-hepatitis-c-drug-developers-rise
has not only created greater competition in the exact same specific
drug class as RG7128, but has given Roche a reason to move sluggish on
the development with Pharmasset when they just purchased and are
producing a drug with a competitor.
- PSI-7977 - is a drug that treats infection after HCV has tore your insides up www.pharmasset.com/pipeline/psi_7851.aspx
because Pharmasset's other drugs, both in production and in trial,
haven't worked. Then regret to inform you that PSI-7977 has only stayed
in production is because its easily produced and remained at low cost,
which infers that it will not pass FDA approval, but still remains "good
on the books" to the board.
- PSI -938 - is just another PSI-7977 www.pharmasset.com/pipeline/psi_938_psi_879.aspx used to treat a patient after other Pharmasset drugs designed to prevent have failed. Phase 1 trial of this drug went awfully in vitro and destroyed key elements of the liver and although there are prospects here we are too far gone for anything to help the stock capitalize in the near future (12-18months)
Huge gap down from terrible earnings, then we get a technical bounce and now, which is what you want to pay attention to, the stock has touched back to the exact same place where it had the huge gap down from 63. Not once, not twice, but 3 times. One of these times it is going to break through and go towards 50, which is my initial price target on selling half of your shares, 63 (sell half), 50 (sell rest)
Recommendation: Short this stock based off of all the evidence I've brought forth to you today and hold it until we get a break below 63, where you can choose to trade how you feel.
I will work on getting you into a winning trade, its up to you to manage it.